Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Orion Pharma's net income from continuing operations for the
three
months ended in Mar. 2026 was BDT-10 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-569 Mil.
Orion Pharma Net Income From Continuing Operations Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Net Income From Continuing Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma Net Income From Continuing Operations Chart
Orion Pharma Net Income From Continuing Operations Calculation
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income From Continuing Operations of BDT-569 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Net Income From Continuing Operations of BDT-569 Mil as of Mar. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Orion Pharma and its competitors.
Is Orion Pharma's Net Income From Continuing Operations too high?
Orion Pharma's current Net Income From Continuing Operations is BDT-569 Mil. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Net Income From Continuing Operations compare to CEG and VST?
Orion Pharma's Net Income From Continuing Operations of BDT-569 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for an Utilities - Independent Power Producers company?
A good Net Income From Continuing Operations depends on the Utilities - Independent Power Producers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Orion Pharma and its competitors. Orion Pharma's current Net Income From Continuing Operations is BDT-569 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.39, compared to a current price of BDT25.00 — trading 28.9% above its estimated fair value. The current Net Income From Continuing Operations is BDT-569 Mil. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Net Income From Continuing Operations is BDT-569 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT25.00 is trading 28.9% above its estimated GF Value™ of BDT19.39.
GuruFocus considers Orion Pharma to be Modestly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Net Income From Continuing Operations: BDT-569 Mil
GF Value™: BDT19.39 vs. price of BDT25.00 (28.9% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
